

# Übersicht der bestätigten und bewerteten Publikationen

Universitätsklinik und Poliklinik für Gynäkologie  
Journalbeitrag

## Originalarbeit

1. Costa S.D., Jackisch C., Thomssen C.: (2010) Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials. BREAST CARE, 5: 22-24 [20847929](#)  
**IF: 0,364; anteiliger IF: 0,12132**
2. Dittmer J.: (2010) Mesenchymal stem cells: "repair cells" that serve wounds and cancer? SCI WORLD J, 10: 1234-8 [20602080](#)  
**IF: 1,524; anteiliger IF: 1,524**
3. Göpel C., Kantelhardt E., Karbe I., Störer S., Dittmer J.: (2010) Changes of glycoprotein and collagen immunolocalization in the uterine artery wall of postmenopausal women with and without pelvic organ prolapse. Acta Histochem (2010), doi:10.1016/j.acthis.2010.02.001. ACTA HISTOCHEMICA, 1: 1-7  
**IF: 1,735; anteiliger IF: 1,735**
4. Guarneri V., Miles D., Robert N., Diéras V., Glaspy J., Smith I., Thomssen C., Biganzoli L., Taran T., Conte P.: (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 122: 181-8 [20361252](#)  
**IF: 4,859; anteiliger IF: 0,2025**
5. Harbeck N., Thomssen C.: (2010) A new look at node-negative breast cancer. ONCOLOGIST, 15 Suppl 5: 29-38 [21278441](#)  
**IF: 5,826; anteiliger IF: 2,913**
6. Huober J., von Minckwitz G., Denkert C., Tesch H., Weiss E., Zahm D.M., Belau A., Khandan F., Hauschild M., Thomssen C., Högel B., Darb-Esfahani S., Mehta K., Loibl S.: (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. BREAST CANCER RESEARCH AND TREATMENT, 124: 133-40 [20697801](#)  
**IF: 4,859; anteiliger IF: 0,135**
7. Konecny G.E., Pauletti G., Untch M., Wang H.J., Möbus V., Kuhn W., Thomssen C., Harbeck N., Wang L., Apple S., Jänicke F., Slamon D.J.: (2010) Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 120: 481-9 [20130985](#)  
**IF: 4,859; anteiliger IF: 0,162**
8. Lebeau A., Turzynski A., Braun S., Behrhof W., Fleige B., Schmitt W.D., Grob T.J., Burkhardt L., Hölzel D., Jackisch C., Thomssen C., Müller V., Untch M.: (2010) Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. JOURNAL OF CLINICAL ONCOLOGY, 28: 3264-70 [20498397](#)  
**IF: 18,97; anteiliger IF: 0,57496**
9. Moebus V., Jackisch C., Lueck H.J., du Bois A., Thomssen C., Kurbacher C., Kuhn W., Nitz U., Schneeweiss A., Huober J., Harbeck N., von Minckwitz G., Runnebaum I.B., Hinke A., Kreienberg R., Konecny G.E., Untch M.: (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. JOURNAL OF CLINICAL ONCOLOGY, 28: 2874-80 [20458045](#)  
**IF: 18,97; anteiliger IF: 0,42164**
10. Müller V., Thomssen C., Schmidt M., Glados M., Jackisch C., Heilmann V., Hinke A., Lehnert A., Borowicz H., Möbus V.: (2010) Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer. BMC CANCER, 10: 430 [20712886](#)  
**IF: 3,153; anteiliger IF: 0,1314**
11. Ronneburg H., Span S.N., Kantelhardt E., Dittmer A., Schunke D., Holzhausen H.J., Sweep F., Dittmer J.: (2010) Rho GDP dissociation inhibitor alfa expression correlates with the outcome of CMF treatment in invasive ductal breast cancer. INTERNATIONAL JOURNAL OF ONCOLOGY, 1: 1-10  
**IF: 2,571; anteiliger IF: 2,14241**
12. Thomssen C., Harbeck N.: (2010) Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - ChapterB: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer. BREAST CARE, 5: 345-351  
**IF: 0,364; anteiliger IF: 0,182**
13. Untch M., Muschöll M., Tjulandin S., Jonat W., Meerpohl H.G., Lichinitser M., Manikhas A.G., Coumbos A., Kreienberg R., du Bois A., Harbeck N., Jackisch C., Müller V., Pauschinger M., Thomssen C., Lehle M., Catalani O., Lück H.J.: (2010) First-line trastuzumab plus epirubicin

and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. JOURNAL OF CLINICAL ONCOLOGY, 28: 1473-80 [20177030](#)

**IF: 18,97; anteiliger IF: 0,39529**

14. Untch M., Rezaei M., Loibl S., Fasching P.A., Huober J., Tesch H., Bauerfeind I., Hilfrich J., Eidtmann H., Gerber B., Hanusch C., Kühn T., du Bois A., Blohmer J.U., Thomssen C., Dan Costa S., Jackisch C., Kaufmann M., Mehta K., von Minckwitz G.: (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. JOURNAL OF CLINICAL ONCOLOGY, 28: 2024-31 [20308670](#)  
**IF: 18,97; anteiliger IF: 0,35137**
15. Untch M., Thomssen C.: (2010) Clinical practice decisions in endocrine therapy. CANCER INVESTIGATION, 28: 4-13 [20653403](#)  
**IF: 2,39; anteiliger IF: 1,195**
16. Vetter M., Kantelhardt E., Thomssen C.: (2010) The determination of prognostic factors uPA and PAI 1 for risk evaluation in nodal negative breast cancer experiences of NNBC3-Europe study. ONKOLOGIE, 33: 25  
**IF: 1,156; anteiliger IF: 1,156**
17. von Minckwitz G., Rezaei M., Loibl S., Fasching P.A., Huober J., Tesch H., Bauerfeind I., Hilfrich J., Eidtmann H., Gerber B., Hanusch C., Kühn T., du Bois A., Blohmer J.U., Thomssen C., Dan Costa S., Jackisch C., Kaufmann M., Mehta K., Untch M.: (2010) Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. JOURNAL OF CLINICAL ONCOLOGY, 28: 2015-23 [20308671](#)  
**IF: 18,97; anteiliger IF: 0,35137**
18. Wynendaele J., Böhnke A., Leucci E., Nielsen S.J., Lambertz I., Hammer S., Sbrzesny N., Kubitzka D., Wolf A., Gradhand E., Balschun K., Braicu I., Sehouli J., Darb-Esfahani S., Denkert C., Thomssen C., Hauptmann S., Lund A., Marine J.C., Bartel F.: (2010) An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. CANCER RESEARCH, 70: 9641-9 [21084273](#)  
**IF: 8,234; anteiliger IF: 0,15251**

**2010 Summe der Bewertungen: 13,84677, Summe IF = 136.74**

### Originalarbeit

1. Blohmer J.U., Paepke S., Sehouli J., Boehmer D., Kolben M., Würschmidt F., Petry K.U., Kimmig R., Elling D., Thomssen C., von Minckwitz G., Möbus V., Hinke A., Kümmel S., Budach V., Lichtenegger W., Schmid P.: (2011) Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. JOURNAL OF CLINICAL ONCOLOGY, 29: 3791-7 [21860000](#)  
**IF: 18,372; anteiliger IF: 0,40786**
2. Dittmer A., Fuchs A., Oerlecke I., Leyh B., Kaiser S., Martens J.W.M., Lützkendorf J., Müller L., Dittmer J.: (2011) Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors. INTERNATIONAL JOURNAL OF ONCOLOGY, 39: 689-96 [21667024](#)  
**IF: 2,399; anteiliger IF: 1,82756**
3. Gerloff A., Dittmer A., Oerlecke I., Holzhausen H.J., Dittmer J.: (2011) Protein expression of the Ets transcription factor Elf-1 in breast cancer cells is negatively correlated with histological grading, but not with clinical outcome. ONCOLOGY REPORTS, 26: 1121-5 [21811762](#)  
**IF: 1,835; anteiliger IF: 1,42714**
4. nant M., Harbeck N., Thomssen C.: (2011) St. Gallen 2011: Summary of the Consensus Discussion. BREAST CARE, 6: 136-141 [21633630](#)  
**IF: 0,446; anteiliger IF: 0,14865**
5. Goepel C., Johanna Kantelhardt E., Karbe I., Stoerer S., Dittmer J.: (2011) Changes of glycoprotein and collagen immunolocalization in the uterine artery wall of postmenopausal women with and without pelvic organ prolapse. ACTA HISTOCHEMICA, 113: 375-81 [20189634](#)  
**IF: 1,829; anteiliger IF: 1,829**
6. Guo X., Loibl S., Untch M., Möbus V., Schwedler K., Fasching P.A., Barinoff J., Holms F., Thomssen C., Zahm D.M., Kreienberg R., Hauschild M., Eidtmann H., Tauchert S., Mehta K., von Minckwitz G.: (2011) Re-Challenging Taxanes in Recurrent Breast Cancer in Patients

- Treated with (Neo-)Adjuvant Taxane-Based Therapy. BREAST CARE, 6: 279-283 [22164126](#)  
**IF: 0,446; anteiliger IF: 0,01062**
7. Huober J., Paepke P.A., Barsoum M., Petruzella L., Wallwiener D., Thomssen C., Reimer T., Paepke S., Azim H.A., Ragosch V., Kubista E., Baumgärtner A.K., Beckmann M.W., May C., Nimmrich I., Harbeck N.: (2011) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial. BREAST, 19: 1-11  
**IF: 2,491; anteiliger IF: 0,05932**
  8. Kantelhardt E.J., Vetter M., Schmidt M., Veyret C., Augustin D., Hanf V., Meisner C., Paepke D., Schmitt M., Sweep F., von Minckwitz G., Martin P.M., Jaenicke F., Thomssen C., Harbeck N.: (2011) Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6x FEC versus 3x FEC/3x Docetaxel. BMC CANCER, 11: 140 [21496284](#)  
**IF: 3,011; anteiliger IF: 1,15801**
  9. Pivot X., Schneeweiss A., Verma S., Thomssen C., Passos-Coelho J.L., Benedetti G., Ciruelos E., von Moos R., Chang H.T., Duenne A.A., Miles D.W.: (2011) Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. EUROPEAN JOURNAL OF CANCER, 47: 2387-95 [21757334](#)  
**IF: 5,536; anteiliger IF: 0,20483**
  10. Schmitt M., Harbeck N., Brünner N., Jänicke F., Meisner C., Mühlenweg B., Jansen H., Dorn J., Nitz U., Kantelhardt E.J., Thomssen C.: (2011) Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 11: 617-34 [21745015](#)  
**IF: 4,859; anteiliger IF: 1,7995**
  11. Smith I., Pierga J.Y., Biganzoli L., Cortes-Funes H., Thomssen C., Saracchini S., Nisenbaum B., Pelaez I., Duenne A.A., Pritchard K.I.: (2011) Final overall survival results and effect of prolonged ( $\geq 1$  year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. BREAST CANCER RESEARCH AND TREATMENT, 130: 133-43 [21830015](#)  
**IF: 4,431; anteiliger IF: 0,18477**
  12. Smith I.E., Pierga J.Y., Biganzoli L., Cortés-Funes H., Thomssen C., Pivot X., Fabi A., Xu B., Stroyakovskiy D., Franke F.A., Kaufman B., Mainwaring P., Pienkowski T., De Valk B., Kwong A., González-Trujillo J.L., Koza I., Petrakova K., Pereira D., Pritchard K.I., ATHENA Study Group: (2011) First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. ANNALS OF ONCOLOGY, 22: 595-602 [20819780](#)  
**IF: 6,425; anteiliger IF: 0,11901**
  13. Stang A., Trocchi P., Ruschke K., Schmidt-Pokrzywniak A., Holzhausen H.J., Löning T., Buchmann J., Thomssen C., Lantsch T., Hauptmann S., Böcker W., Kluttig A.: (2011) Factors influencing the agreement on histopathological assessments of breast biopsies among pathologists. HISTOPATHOLOGY, 59: 939-49 [22092405](#)  
**IF: 3,082; anteiliger IF: 0,10263**
  14. Thomssen C., Scharl A., Harbeck N.: (2011) AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011. BREAST CARE, 6: 299-313 [22164127](#)  
**IF: 0,446; anteiliger IF: 0,14865**
  15. Witzel I., Kantelhardt E.J., Milde-Langosch K., Ihnen M., Zeitz J., Harbeck N., Jänicke F., Müller V.: (2011) Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer. ONKOLOGIE, 34: 304-8 [21625183](#)  
**IF: 0,868; anteiliger IF: 0,04823**

**2011 Summe der Bewertungen: 9,47579, Summe IF = 56.48**

#### **Originalarbeit**

1. Bartel F., Balschun K., Gradhand E., Strauss H.G., Dittmer J., Hauptmann S.: (2012) Cyr61/ccn1. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 31: 405-415  
**IF: 1,413; anteiliger IF: 0,11777**
2. Bartel F., Balschun K., Gradhand E., Strauss H.G., Dittmer J., Hauptmann S.: (2012) Inverse expression of cysteine-rich 61 (Cyr61/CCN1) and connective tissue growth factor (CTGF/CCN2) in borderline tumors and carcinomas of the ovary. INTERNATIONAL

3. Braun G., Führer A., Breitenstein E., Tariku W., Abdelbaghi O., Hauptmann S., Bogale S., Kantelhardt E.: (2012) Cancer in Africa: AORTIC 8th International Cancer Conference 'Entering the 21st Century for Cancer Control in Africa' 30.11.-2.12.2011. BREAST CARE, 7: 177-179 [22740807](#)  
**IF: 0,68; anteiliger IF: 0,22664**
4. Cardoso F., Costa A., Norton L., Cameron D., Cufer T., Fallowfield L., Francis P., Gligorov J., Kyriakides S., Lin N., Pagani O., Senkus E., Thomssen C., Aapro M., Bergh J., Di Leo A., El Saghir N., Ganz P.A., Gelmon K., Goldhirsch A., Harbeck N., Houssami N., Hudis C., Kaufman B., Leadbeater M., Mayer M., Rodger A., Rugo H., Sacchini V., Sledge G., van't Veer L., Viale G., Krop I., Winer E.: (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). BREAST, 21: 242-52 [22425534](#)  
**IF: 1,967; anteiliger IF: 0,02049**
5. Hardt O., Wild S., Oerlecke L., Hofmann K., Luo S., Wiencek Y., Kantelhardt E., Vess C., Smith G.P., Schroth G.P., Bosio A., Dittmer J.: (2012) Highly sensitive profiling of CD44+/CD24- breast cancer stem cells by combining global mRNA amplification and next generation sequencing: evidence for a hyperactive PI3K pathway. CANCER LETTERS, 325: 165-74 [22771536](#)  
**IF: 4,258; anteiliger IF: 1,70277**
6. Huober J., Fasching P.A., Barsoum M., Petruzella L., Wallwiener D., Thomssen C., Reimer T., Paepke S., Azim H.A., Ragosch V., Kubista E., Baumgärtner A.K., Beckmann M.W., May C., Nimmrich I., Harbeck N.: (2012) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. BREAST, 21: 27-33 [21862331](#)  
**IF: 1,967; anteiliger IF: 0,04684**
7. Loehberg C.R., Strissel P.L., Dittrich R., Strick R., Dittmer J., Dittmer A., Fabry B., Kalender W.A., Koch T., Wachter D.L., Groh N., Polier A., Brandt I., Lotz L., Hoffmann I., Koppitz F., Oeser S., Mueller A., Fasching P.A., Lux M.P., Beckmann M.W., Schrauder M.G.: (2012) Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001. BIOCHEMICAL PHARMACOLOGY, 83: 480-8 [22142888](#)  
**IF: 4,576; anteiliger IF: 0,15256**
8. Surov A., Holzhausen H.J., Wienke A., Schmidt J., Thomssen C., Arnold D., Ruschke K., Spielmann R.P.: (2012) Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features. BRITISH JOURNAL OF RADIOLOGY, 85: e195-205 [22665932](#)  
**IF: 1,217; anteiliger IF: 0,06762**
9. Thomssen C.: (2012) [Is non-oral hormonal contraception really free of risks? Comment on the case report by Spinner et al]. INTERNIST, 53: 982-4 [22825782](#)  
**IF: 0,329; anteiliger IF: 0,329**
  
10. Thomssen C., Marschner N., Untch M., Decker T., Hegewisch-Becker S., Jackisch C., Janni W., Hans-Joachim L., von Minckwitz G., Scharl A., Schneeweiss A., Tesch H., Welt A., Harbeck N.: (2012) ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011. BREAST CARE, 7: 52-59 [22553474](#)  
**IF: 0,68; anteiliger IF: 0,22664**
11. Thomssen C., Pierga J.Y., Pritchard K.I., Biganzoli L., Cortes-Funes H., Petráková K., Kaufman B., Duenne A., Smith I.: (2012) First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. ONCOLOGY, 82: 218-27 [22508241](#)  
**IF: 2,165; anteiliger IF: 0,72159**
12. Trocchi P., Ursin G., Kuss O., Ruschke K., Schmidt-Pokrzywniak A., Holzhausen H.J., Löning T., Thomssen C., Böcker W., Kluttig A., Stang A.: (2012) Mammographic density and inter-observer variability of pathologic evaluation of core biopsies among women with mammographic abnormalities. BMC CANCER, 12: 554 [23176326](#)  
**IF: 3,333; anteiliger IF: 0,12347**
13. Wagner A.D., Thomssen C., Haerting J., Unverzagt S.: (2012) Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database of Systematic Reviews, 7: CD008941 [22786517](#)  
**IF: 5,785; anteiliger IF: 0,96436**
14. Wenners A.S., Mehta K., Loibl S., Park H., Mueller B., Arnold N., Hamann S., Weimer J., Ataseven B., Darb-Esfahani S., Schem C., Mundhenke C., Khandan F., Thomssen C., Jonat W., Holzhausen H.J., von Minckwitz G., Denkert C., Bauer M.: (2012) Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical

**2012 Summe der Bewertungen: 4,89071, Summe IF = 33.51**

### Originalarbeit

1. Amant F., von Minckwitz G., Han S.N., Bontenbal M., Ring A.E., Giermek J., Wildiers H., Fehm T., Linn S.C., Schlehe B., Neven P., Westenend P.J., Müller V., Van Calsteren K., Rack B., Nekljudova V., Harbeck N., Untch M., Witteveen P.O., Schwedler K., Thomssen C., Van Calster B., Loibl S.: (2013) Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. JOURNAL OF CLINICAL ONCOLOGY, 31: 2532-9 [23610117](#)  
**IF: 17,96; anteiliger IF: 0,28514**
2. Dittmer J., Rody A.: (2013) Cancer stem cells in breast cancer. HISTOLOGY AND HISTOPATHOLOGY, 28: 827-38 [23468411](#)  
**IF: 2,236; anteiliger IF: 1,118**
3. du Bois A., Ewald-Riegler N., de Gregorio N., Reuss A., Mahner S., Fotopoulou C., Kommos F., Schmalfeldt B., Hilpert F., Fehm T., Burges A., Meier W., Hillemanns P., Hanker L., Hasenburg A., Strauss H.G., Hellriegel M., Wimberger P., Keyver-Paik M.D., Baumann K., Canzler U., Wollschlaeger K., Forner D., Pfisterer J., Schröder W., Münstedt K., Richter B., Kommos S., Hauptmann S., Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group: (2013) Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group. EUROPEAN JOURNAL OF CANCER, 49: 1905-14 [23490647](#)  
**IF: 4,819; anteiliger IF: 0,05949**
4. Emons G., Güntherth A., Thiel F.C., Camara O., Strauss H.G., Breitbach G.P., Kölbl H., Reimer T., Finas D., Rensing K., Arbeitsgemeinschaft Gynäkologische Onkologie (AGO): (2013) Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie. GYNECOLOGIC ONCOLOGY, 129: 495-9 [23500091](#)  
**IF: 3,687; anteiliger IF: 0,13656**
5. Harbeck N., Scharl A., Thomssen C., Müller V.: (2013) AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013. BREAST CARE, 8: 181-5 [24415967](#)  
**IF: 0,911; anteiliger IF: 0,15183**
6. Harbeck N., Thomssen C., Gnant M.: (2013) St. Gallen 2013: brief preliminary summary of the consensus discussion. BREAST CARE, 8: 102-9 [24000280](#)  
**IF: 0,911; anteiliger IF: 0,30367**
7. Lantzsch T., Lampe D., Kantelhardt E.J.: (2013) Correction of Poland's Syndrome: Case Report and Review of the Current Literature. BREAST CARE, 8: 139-42 [24419214](#)  
**IF: 0,911; anteiliger IF: 0,30367**
8. Lin N.U., Thomssen C., Cardoso F., Cameron D., Cufer T., Fallowfield L., Francis P.A., Kyriakides S., Pagani O., Senkus E., Costa A., Winer E.P., European School of Oncology-Metastatic Breast Cancer Task Force: (2013) International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. BREAST, 22: 203-10 [23601761](#)  
**IF: 2,581; anteiliger IF: 0,07823**
9. Lück H.J., Du Bois A., Loibl S., Schrader I., Huober J., Heilmann V., Beckmann M., Stähler A., Jackisch C., Hubalek M., Richter B., Stickeler E., Eidtmann H., Thomssen C., Untch M., Wollschläger K., Schuster T., von Minckwitz G.: (2013) Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. BREAST CANCER RESEARCH AND TREATMENT, 139: 779-87 [23771714](#)  
**IF: 4,198; anteiliger IF: 0,08746**
10. Moebus V., Jackisch C., Schneeweiss A., Huober J., Lueck H.J., du Bois A., Thomssen C., Kurbacher C., Kuhn W., Nitz U., Runnebaum I.B., Hinke A., Kreienberg R., Untch M., AGO Breast Cancer Study Group: (2013) Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. JNCI-Journal of the National Cancer Institute, 105: 1018-26 [23860204](#)  
**IF: 15,161; anteiliger IF: 0,38874**

11. Oerlecke I., Bauer E., Dittmer A., Leyh B., Dittmer J.: (2013) Cyclic AMP enhances TGF $\beta$  responses of breast cancer cells by upregulating TGF $\beta$  receptor I expression. PLoS One, 8: e54261 [23349840](#)  
**IF: 3,534; anteiliger IF: 3,53376**
12. Scharl A., Thomssen C., Harbeck N., Müller V.: (2013) AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013. BREAST CARE, 8: 174-80 [24415966](#)  
**IF: 0,911; anteiliger IF: 0,15183**
13. Thomssen C., Diel I., Gnant M., Goldmann-Posch U., Göschke C., Haidinger R., Janni W., Lin N.U.: (2013) Follow-up after breast cancer diagnosis. BREAST CARE, 8: 457-60 [24550757](#)  
**IF: 0,911; anteiliger IF: 0,30367**
14. Thomssen C., Harbeck N.: (2013) ABC2 Consensus Conference on Advanced Breast Cancer: Brief Summary of the Consensus Panel on Saturday November 9, 2013. BREAST CARE, 8: 455-6 [24550756](#)  
**IF: 0,911; anteiliger IF: 0,4555**
15. Trocchi P., Holzhausen H.J., Böcker W., Schmidt-Pokrzywniak A., Ruschke K., Thomssen C., Löning T., Kluttig A., Stang A.: (2013) Influence of immunohistochemistry on the final diagnosis of breast biopsies. HISTOPATHOLOGY, 63: 817-25 [24236511](#)  
**IF: 3,301; anteiliger IF: 0,15719**
16. Untch M., Gerber B., Harbeck N., Jackisch C., Marschner N., Möbus V., von Minckwitz G., Loibl S., Beckmann M.W., Blohmer J.U., Costa S.D., Decker T., Diel I., Dimpfl T., Eiermann W., Fehm T., Friese K., Jänicke F., Janni W., Jonat W., Kiechle M., Köhler U., Lück H.J., Maass N., Possinger K., Rody A., Scharl A., Schneeweiss A., Thomssen C., Wallwiener D., Welt A.: (2013) 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). BREAST CARE, 8: 221-9 [24415975](#)  
**IF: 0,911; anteiliger IF: 0,01047**
17. von Minckwitz G., Möbus V., Schneeweiss A., Huober J., Thomssen C., Untch M., Jackisch C., Diel I.J., Elling D., Conrad B., Kreienberg R., Müller V., Lück H.J., Bauerfeind I., Clemens M., Schmidt M., Noeding S., Forstbauer H., Barinoff J., Belau A., Nekljudova V., Harbeck N., Loibl S.: (2013) German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 31: 3531-9 [23980081](#)  
**IF: 17,96; anteiliger IF: 0,28508**

**2013 Summe der Bewertungen: 7,81029, Summe IF = 81.81**

### **Originalarbeit**

1. Dittmer J., Leyh B.: (2014) Paracrine effects of stem cells in wound healing and cancer progression (Review). INTERNATIONAL JOURNAL OF ONCOLOGY, 44: 1789-98 [24728412](#)  
**IF: 3,025; anteiliger IF: 3,025**
2. Harbeck N., Marschner N., Untch M., Decker T., Hegewisch-Becker S., Jackisch C., Huober J., Lück H.J., von Minckwitz G., Scharl A., Schneeweiss A., Tesch H., Welt A., Wuerstlein R., Thomssen C.: (2014) Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective. BREAST CARE, 9: 52-9 [24803888](#)  
**IF: 0,627; anteiliger IF: 0,20898**
3. Horn L.C., Bauerfeind U.K., Strau H.G., Karbe I.: (2014) Vulval intestinal/enteric heterotopia with a 10-yr follow-up: a case report and review of the literature. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 33: 258-62 [24681736](#)  
**IF: 1,665; anteiliger IF: 1,11006**
4. Kantelhardt E.J., Zerche P., Mathewos A., Trocchi P., Addissie A., Aynalem A., Wondemagegnehu T., Ersumo T., Reeler A., Yonas B., Tinsae M., Gemechu T., Jemal A., Thomssen C., Stang A., Bogale S.: (2014) Breast cancer survival in Ethiopia: a cohort study of 1,070 women. INTERNATIONAL JOURNAL OF CANCER, 135: 702-9 [24375396](#)  
**IF: 5,085; anteiliger IF: 0,24209**
5. Kantelhardt E.J., Mathewos A., Aynalem A., Wondemagegnehu T., Jemal A., Vetter M., Knauf E., Reeler A., Bogale S., Thomssen C., Stang A., Gemechu T., Trocchi P., Yonas B.: (2014) The prevalence of estrogen receptor-negative breast cancer in Ethiopia. BMC CANCER, 14:

895 [25433805](#)

**IF: 3,362; anteiliger IF: 1,40106**

6. Kantelhardt E.J., Moelle U., Begoihn M., Addissie A., Trocchi P., Yonas B., Hezkiel P., Stang A., Thomssen C., Vordermark D., Gemechu T., Gebrehiwot Y., Wondemagegnehu T., Aynalem A., Mathewos A.: (2014) Cervical cancer in Ethiopia: survival of 1,059 patients who received oncologic therapy. ONCOLOGIST, 19: 727-34 [24951611](#)  
**IF: 4,865; anteiliger IF: 1,87075**
7. Schlitt A., Jordan K., Vordermark D., Schwamborn J., Langer T., Thomssen C.: (2014) Cardiotoxicity and oncological treatments. Deutsches Arzteblatt International, 111: 161-8 [24666651](#)  
**IF: 3,518; anteiliger IF: 1,17267**
8. Trillsch F., Mahner S., Woelber L., Vettorazzi E., Reuss A., Ewald-Riegler N., de Gregorio N., Fotopoulou C., Schmalfeldt B., Burges A., Hilpert F., Fehm T., Meier W., Hillemanns P., Hanker L., Hasenburg A., Strauss H.G., Hellriegel M., Wimberger P., Baumann K., Keyver-Paik M.D., Canzler U., Wollschlaeger K., Forner D., Pfisterer J., Schroeder W., Muenstedt K., Richter B., Kommos F., Hauptmann S., du Bois A.: (2014) Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. ANNALS OF ONCOLOGY, 25: 1320-7 [24618151](#)  
**IF: 7,04; anteiliger IF: 0,08092**
9. Wichmann H., Güttler A., Bache M., Taubert H., Vetter M., Würfl P., Holzhausen H.J., Eckert A.W., Kappler M., Vordermark D.: (2014) Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients. STRAHLENTHERAPIE UND ONKOLOGIE, 190: 912-8 [24715245](#)  
**IF: 2,914; anteiliger IF: 0,12142**

**2014 Summe der Bewertungen: 9,23294, Summe IF = 32.1**

#### **Originalarbeit**

1. Denschlag D., Thiel F.C., Ackermann S., Harter P., Juhasz-Boess I., Mallmann P., Strauss H.G., Ulrich U., Horn L.C., Schmidt D., Vordermark D., Vogl T., Reichardt P., Gaß P., Gebhardt M., Beckmann M.W.: (2015) Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). GEBURTSHILFE UND FRAUENHEILKUNDE, 75: 1028-1042 [26640293](#)  
**IF: 0,931; anteiliger IF: 0,02217**
2. Dittmer J.: (2015) The role of the transcription factor Ets1 in carcinoma. SEMINARS IN CANCER BIOLOGY, 35: 20-38 [26392377](#)  
**IF: 9,955; anteiliger IF: 9,955**
3. Dittmer J., Leyh B.: (2015) The impact of tumor stroma on drug response in breast cancer. SEMINARS IN CANCER BIOLOGY, 31: 3-15 [24912116](#)  
**IF: 9,955; anteiliger IF: 9,955**
4. Eggemann H., Ignatov T., Burger E., Kantelhardt E.J., Fettke F., Thomssen C., Costa S.D., Ignatov A.: (2015) Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. ENDOCRINE-RELATED CANCER, 22: 725-33 [26187126](#)  
**IF: 4,472; anteiliger IF: 0,49689**
5. Erber R., Gluz O., Brünner N., Kreipe H.H., Pelz E., Kates R., Bartels A., Huober J., Mohrmann S., Moustafa Z., Liedtke C., Möbus V., Augustin D., Thomssen C., Jänicke F., Kiechle M., Kuhn W., Nitz U., Harbeck N., Hartmann A.: (2015) Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. BREAST CANCER RESEARCH AND TREATMENT, 150: 279-88 [25721604](#)  
**IF: 4,085; anteiliger IF: 0,07565**
6. Farthmann J., Hasenburg A., Weil M., Fotopoulou C., Ewald-Riegler N., du Bois O., Trillsch F., Mahner S., Strauss H.G., Wimberger P., Reuss A., du Bois A.: (2015) Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study. SUPPORTIVE CARE IN CANCER, 23: 117-23 [24996831](#)  
**IF: 2,535; anteiliger IF: 0,0845**
7. Gnant M., Thomssen C., Harbeck N.: (2015) St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. BREAST CARE, 10: 124-30 [26195941](#)  
**IF: 1,645; anteiliger IF: 0,54833**

8. Heil J., Kümmel S., Schaefgen B., Paepke S., Thomssen C., Rauch G., Ataseven B., Große R., Dreesmann V., Kühn T., Loibl S., Blohmer J.U., von Minckwitz G.: (2015) Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. BRITISH JOURNAL OF CANCER, 113: 1565-70 [26554654](#)  
**IF: 5,569; anteiliger IF: 0,33752**
9. Jackisch C., Harbeck N., Huober J., von Minckwitz G., Gerber B., Kreipe H.H., Liedtke C., Marschner N., Möbus V., Scheithauer H., Schneeweiss A., Thomssen C., Loibl S., Beckmann M.W., Blohmer J.U., Costa S.D., Decker T., Diel I., Fasching P.A., Fehm T., Janni W., Lück H.J., Maass N., Scharl A., Untch M.: (2015) 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. BREAST CARE, 10: 211-9 [26557827](#)  
**IF: 1,645; anteiliger IF: 0,02384**
10. Kantelhardt E.J., Muluken G., Sefonias G., Wondimu A., Gebert H.C., Unverzagt S., Addissie A.: (2015) A Review on Breast Cancer Care in Africa. BREAST CARE, 10: 364-70 [26989354](#)  
**IF: 1,645; anteiliger IF: 0,65805**
11. Kantelhardt E.J., Cubasch H., Hanson C.: (2015) Taking on breast cancer in East Africa: global challenges in breast cancer. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 27: 108-14 [25490377](#)  
**IF: 2,134; anteiliger IF: 0,71133**
12. Leyh B., Dittmer A., Lange T., Martens J.W.M., Dittmer J.: (2015) Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis. ONCOTARGET, 6: 39307-28 [26515727](#)  
**IF: 5,008; anteiliger IF: 4,45156**
13. Mahner S., Jueckstock J., Hilpert F., Neuser P., Harter P., de Gregorio N., Hasenburg A., Sehoul J., Habermann A., Hillemanns P., Fuerst S., Strauss H.G., Baumann K., Thiel F., Mustea A., Meier W., du Bois A., Griebel L.F., Woelber L., AGO-CaRE 1 investigators: (2015) Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. JNCI-Journal of the National Cancer Institute, 107: 1-10 [25618900](#)  
**IF: 11,37; anteiliger IF: 0,21056**
14. Trillsch F., Mahner S., Vettorazzi E., Woelber L., Reuss A., Baumann K., Keyver-Paik M.D., Canzler U., Wollschlaeger K., Forner D., Pfisterer J., Schroeder W., Muenstedt K., Richter B., Fotopoulou C., Schmalfeldt B., Burges A., Ewald-Riegler N., de Gregorio N., Hilpert F., Fehm T., Meier W., Hillemanns P., Hanker L., Hasenburg A., Strauss H.G., Hellriegel M., Wimberger P., Kommos S., Kommos F., Hauptmann S., du Bois A.: (2015) Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. BRITISH JOURNAL OF CANCER, 112: 660-6 [25562434](#)  
**IF: 5,569; anteiliger IF: 0,06188**
15. Untch M., Harbeck N., Huober J., von Minckwitz G., Gerber B., Kreipe H.H., Liedtke C., Marschner N., Möbus V., Scheithauer H., Schneeweiss A., Thomssen C., Jackisch C., Beckmann M.W., Blohmer J.U., Costa S.D., Decker T., Diel I., Fasching P.A., Fehm T., Janni W., Lück H.J., Maass N., Scharl A., Loibl S.: (2015) Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). GEBURTSHILFE UND FRAUENHEILKUNDE, 75: 556-565 [26166836](#)  
**IF: 0,931; anteiliger IF: 0,01349**
16. von Minckwitz G., Conrad B., Reimer T., Decker T., Eidtmann H., Eiermann W., Hackmann J., Möbus V., Marmé F., Potenberg J., Stickeler E., Simon E., Thomssen C., Huober J., Denkert C., Alfer J., Jackisch C., Nekljudova V., Burchardi N., Loibl S., German Breast Group Investigators: (2015) A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). CANCER, 121: 3639-48 [26111104](#)  
**IF: 5,649; anteiliger IF: 0,09911**

**2015 Summe der Bewertungen: 27,70487, Summe IF = 73.1**

#### **Comment/Letter**

1. Stang A., Kantelhardt E.: (2013) Too many statistical errors for meaningful interpretation. BREAST CANCER RESEARCH AND TREATMENT, 138: 643-4 [23417360](#)  
**IF: 4,198; anteiliger IF: 0,2099**



### Comment/Letter

1. Aapro M.S., De Laurentiis M., Mamounas E., Martin M., Rea D., Rouzier R., Smit V., Thomssen C.: (2014) 14p \* adoption of multi-gene assays in hr +, her2- breast cancer (bc) patients in europe: results of the multidisciplinary application of genomics in clinical practice (magic) survey. ANNALS OF ONCOLOGY, 25 Suppl 1: i5-i6 [24764428](#)  
**IF: 7,04; anteiliger IF: 0,23467**
2. Thomssen C., Harbeck N.: (2014) Cutting-edge therapy concepts - cure metastatic breast cancer? BREAST CARE, 9: 5-6 [24803880](#)  
**IF: 0,627; anteiliger IF: 0,03135**

### Originalarbeit

1. Denschlag D., Thiel F.C., Ackermann S., Harter P., Juhasz-Boess I., Mallmann P., Strauss H.G., Ulrich U., Horn L.C., Schmidt D., Vordermark D., Vogl T., Reichardt P., Gaß P., Gebhardt M., Beckmann M.W.: (2015) Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). GEBURTSHILFE UND FRAUENHEILKUNDE, 75: 1028-1042 [26640293](#)  
**IF: 0,931; anteiliger IF: 0,02217**
2. Dittmer J.: (2015) The role of the transcription factor Ets1 in carcinoma. SEMINARS IN CANCER BIOLOGY, 35: 20-38 [26392377](#)  
**IF: 9,955; anteiliger IF: 9,955**
3. Dittmer J., Leyh B.: (2015) The impact of tumor stroma on drug response in breast cancer. SEMINARS IN CANCER BIOLOGY, 31: 3-15 [24912116](#)  
**IF: 9,955; anteiliger IF: 9,955**
4. Eggemann H., Ignatov T., Burger E., Kantelhardt E.J., Fettke F., Thomssen C., Costa S.D., Ignatov A.: (2015) Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. ENDOCRINE-RELATED CANCER, 22: 725-33 [26187126](#)  
**IF: 4,472; anteiliger IF: 0,49689**
5. Erber R., Gluz O., Brünner N., Kreipe H.H., Pelz E., Kates R., Bartels A., Huober J., Mohrmann S., Moustafa Z., Liedtke C., Möbus V., Augustin D., Thomssen C., Jänicke F., Kiechle M., Kuhn W., Nitz U., Harbeck N., Hartmann A.: (2015) Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. BREAST CANCER RESEARCH AND TREATMENT, 150: 279-88 [25721604](#)  
**IF: 4,085; anteiliger IF: 0,07565**
6. Farthmann J., Hasenburg A., Weil M., Fotopoulou C., Ewald-Riegler N., du Bois O., Trillsch F., Mahner S., Strauss H.G., Wimberger P., Reuss A., du Bois A.: (2015) Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study. SUPPORTIVE CARE IN CANCER, 23: 117-23 [24996831](#)  
**IF: 2,535; anteiliger IF: 0,0845**
7. Gnant M., Thomssen C., Harbeck N.: (2015) St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. BREAST CARE, 10: 124-30 [26195941](#)  
**IF: 1,645; anteiliger IF: 0,54833**
8. Heil J., Kümmel S., Schaeffgen B., Paepke S., Thomssen C., Rauch G., Ataseven B., Große R., Dreesmann V., Kühn T., Loibl S., Blohmer J.U., von Minckwitz G.: (2015) Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. BRITISH JOURNAL OF CANCER, 113: 1565-70 [26554654](#)  
**IF: 5,569; anteiliger IF: 0,33752**
9. Jackisch C., Harbeck N., Huober J., von Minckwitz G., Gerber B., Kreipe H.H., Liedtke C., Marschner N., Möbus V., Scheithauer H., Schneeweiss A., Thomssen C., Loibl S., Beckmann M.W., Blohmer J.U., Costa S.D., Decker T., Diel I., Fasching P.A., Fehm T., Janni W., Lück H.J., Maass N., Scharl A., Untch M.: (2015) 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. BREAST CARE, 10: 211-9 [26557827](#)  
**IF: 1,645; anteiliger IF: 0,02384**

10. Kantelhardt E.J., Muluken G., Sefonias G., Wondimu A., Gebert H.C., Unverzagt S., Addissie A.: (2015) A Review on Breast Cancer Care in Africa. BREAST CARE, 10: 364-70 [26989354](#)  
**IF: 1,645; anteiliger IF: 0,65805**
11. Kantelhardt E.J., Cubasch H., Hanson C.: (2015) Taking on breast cancer in East Africa: global challenges in breast cancer. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 27: 108-14 [25490377](#)  
**IF: 2,134; anteiliger IF: 0,71133**
12. Leyh B., Dittmer A., Lange T., Martens J.W.M., Dittmer J.: (2015) Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis. ONCOTARGET, 6: 39307-28 [26515727](#)  
**IF: 5,008; anteiliger IF: 4,45156**
13. Mahner S., Jueckstock J., Hilpert F., Neuser P., Harter P., de Gregorio N., Hasenburg A., Sehoul J., Habermann A., Hillemanns P., Fuerst S., Strauss H.G., Baumann K., Thiel F., Mustea A., Meier W., du Bois A., Griebel L.F., Woelber L., AGO-CaRE 1 investigators: (2015) Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. JNCI-Journal of the National Cancer Institute, 107: 1-10 [25618900](#)  
**IF: 11,37; anteiliger IF: 0,21056**
14. Trillsch F., Mahner S., Vettorazzi E., Woelber L., Reuss A., Baumann K., Keyver-Paik M.D., Canzler U., Wollschlaeger K., Forner D., Pfisterer J., Schroeder W., Muenstedt K., Richter B., Fotopoulou C., Schmalfeldt B., Burges A., Ewald-Riegler N., de Gregorio N., Hilpert F., Fehm T., Meier W., Hillemanns P., Hanker L., Hasenburg A., Strauss H.G., Hellriegel M., Wimberger P., Kommos S., Kommos F., Hauptmann S., du Bois A.: (2015) Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. BRITISH JOURNAL OF CANCER, 112: 660-6 [25562434](#)  
**IF: 5,569; anteiliger IF: 0,06188**
15. Untch M., Harbeck N., Huober J., von Minckwitz G., Gerber B., Kreipe H.H., Liedtke C., Marschner N., Möbus V., Scheithauer H., Schneeweiss A., Thomssen C., Jackisch C., Beckmann M.W., Blohmer J.U., Costa S.D., Decker T., Diel I., Fasching P.A., Fehm T., Janni W., Lück H.J., Maass N., Scharl A., Loibl S.: (2015) Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). GEBURTSHILFE UND FRAUENHEILKUNDE, 75: 556-565 [26166836](#)  
**IF: 0,931; anteiliger IF: 0,01349**
16. von Minckwitz G., Conrad B., Reimer T., Decker T., Eidtmann H., Eiermann W., Hackmann J., Möbus V., Marmé F., Potenberg J., Stickeler E., Simon E., Thomssen C., Huober J., Denkert C., Alfer J., Jackisch C., Nekljudova V., Burchardi N., Loibl S., German Breast Group Investigators: (2015) A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). CANCER, 121: 3639-48 [26111104](#)  
**IF: 5,649; anteiliger IF: 0,09911**

#### **Comment/Letter**

17. Hermelink K., Berndt U., Haidinger R.: (2015) Alleviating the Breast Cancer Experience: A Plea for Psycho-Oncology. BREAST CARE, 10: 82-3 [26195934](#)  
**IF: 1,645; anteiliger IF: 0,05483**

**2015 Summe der Bewertungen: 27,7597, Summe IF = 73.1**